Your browser doesn't support javascript.
loading
Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults.
Majhail, Navneet S; Mau, Lih-Wen; Chitphakdithai, Pintip; Denzen, Ellen M; Joffe, Steven; Lee, Stephanie J; LeMaistre, Charles F; Loberiza, Fausto; Parsons, Susan K; Repaczki-Jones, Ramona; Robinett, Pam; Douglas Rizzo, J; Murphy, Elizabeth; Logan, Brent; Le-Rademacher, Jennifer.
Afiliação
  • Majhail NS; Blood & Marrow Transplant Program, Cleveland Clinic, Cleveland, OH, USA. majhain@ccf.org.
  • Mau LW; National Marrow Donor Program, Minneapolis, MN, USA.
  • Chitphakdithai P; Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA.
  • Denzen EM; National Marrow Donor Program, Minneapolis, MN, USA.
  • Joffe S; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Lee SJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • LeMaistre CF; Sarah Cannon, Nashville, TN, USA.
  • Loberiza F; Pfizer Oncology, Omaha, NE, USA.
  • Parsons SK; Center for Health Solutions, Tufts Medical Center, Boston, MA, USA.
  • Repaczki-Jones R; Blood and Marrow Transplant Program, Moffitt Cancer Center, Tampa, FL, USA.
  • Robinett P; National Marrow Donor Program, Minneapolis, MN, USA.
  • Douglas Rizzo J; Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA.
  • Murphy E; National Marrow Donor Program, Minneapolis, MN, USA.
  • Logan B; Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA.
  • Le-Rademacher J; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Bone Marrow Transplant ; 55(5): 906-917, 2020 05.
Article em En | MEDLINE | ID: mdl-31740767
Allogeneic hematopoietic cell transplantation (alloHCT) is a highly specialized procedure. We surveyed adult transplant centers in the United States (US) and then used data reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) (2008-2010) to evaluate associations of center volume, infrastructure, and care delivery models with survival post alloHCT. Based on their 2010 alloHCT volume, centers were categorized as low-volume (≤40 alloHCTs; N = 42 centers, 1900 recipients) or high-volume (>40 alloHCTs; N = 41 centers, 9637 recipients). 100-day survival was 86% (95% CI, 85-87%) in high-volume compared with 83% (95% CI, 81-85%) in low-volume centers (difference 3%; P < 0.001). One-year survival was 62% (95% CI, 61-63%) and 56% (95% CI, 54-58%), respectively (difference 6%; P < 0.001). Logistic regression analyses adjusted for patient and center characteristics; alloHCT at high-volume centers (odds ratio [OR] 1.32; P < 0.001) and presence of a survivorship program dedicated to HCT recipients (OR 1.23; P = 0.009) were associated with favorable 1-year survival compared to low-volume centers. Similar findings were observed in a CIBMTR validation cohort (2012-2014); high-volume centers had better 1-year survival (OR 1.24, P < 0.001). Among US adult transplant centers, alloHCT at high-volume centers and at centers with survivorship programs is associated with higher 1-year survival.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Transplantes Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Transplantes Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2020 Tipo de documento: Article